Erschienen in:
25.01.2020 | Observational Research
A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3
verfasst von:
Marta Novella-Navarro, Jose Luis Cabrera-Alarcon, Cesar Diaz-Torne, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, Luis Sala-Icardo, Ana Urruticoechea-Arana, Paloma García de la Peña Lefebvre, Enrique Calvo-Aranda
Erschienen in:
Rheumatology International
|
Ausgabe 7/2020
Einloggen, um Zugang zu erhalten
Abstract
The aim of this study was to assess changes in the estimated glomerular filtration rate (eGFR) in gouty patients with chronic kidney disease (CKD) using a “treat-to-target” (T2T) approach in gout. This multicenter observational retrospective study included patients diagnosed with gout and CKD stage 3 taking xanthine oxidase inhibitors (XOIs) (allopurinol or febuxostat) for at least 12 months. All patients were treated using a T2T strategy according to national gout guidelines to achieve the target levels of serum uric acid (sUA; < 5–6 mg/dl) within 6 months of the first visit. The primary outcome was to assess changes in eGFR. The effects of independent variables were analyzed over eGFR in a linear mixed-effects (LME) model. Fifty patients with gout and CKD stage 3 treated with XOIs with a T2T strategy for 12 months were included. Eighty-two percent of the patients achieved the sUA target during the study period. The improvement seen in eGFR was higher during the first 6 months, showing a median increase of 7.54 ml/min/m2 (SE = 1.25) and trending towards stability over 12 months. For every 1 mg/dl of decrease in sUA, an improvement of 1.5 ml/min/m2 in eGFR was observed (coefficient ± SE: − 1.58 ± 0.26) (p < 0.001) with no differences between type and dosage of XOIs treatment, colchicine administration, age, sex, and smoking status. A reduction in sUA levels using a T2T approach with XOIs at an optimal dose is possible and could help conserve and improve renal function in gouty patients with CKD stage 3.